|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 6,465,464: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 6,465,464 (hereafter, “the ‘464 patent”) was granted on October 15, 2002, to Bayer AG. The patent pertains to a specific formulation and method related to a pharmaceutical composition, with particular emphasis on its compound structure, method of manufacturing, and therapeutic applications.
This patent's scope primarily revolves around a stabilized oral dosage formulation of 2-[(4-isocyanatophenyl)amino]-4-methylpentanoic acid derivatives, which are known for their anti-inflammatory and immunomodulatory effects, notably akin to methotrexate analogs used in rheumatoid arthritis treatment.
The patent landscape surrounding this IP is characterized by a moderately broad set of claims focused on the composition, methods of preparation, and therapeutic uses, creating a competitive environment among innovator and biosimilar firms. This report dissects the patent claims, assesses the scope’s breadth, explores ongoing litigation and patent filings, and contextualizes the patent in the broader pharmaceutical innovation landscape.
I. Patent Overview and Key Data
| Patent Number |
6,465,464 |
| Filing Date |
August 27, 1998 |
| Issue Date |
October 15, 2002 |
| Assignee |
Bayer Aktiengesellschaft (Germany) |
| Inventors |
Ulrich Bock, et al. |
| Patent Term |
20 years from filing (expires in 2018, subject to patent term adjustments) |
Note: The patent, now expired, historically provided exclusivity protection extending into 2018, influencing the development and marketing of related antirheumatic drugs.
II. Scope of the Patent: Claims Breakdown
A. Key Focus of the Claims
The patent claims encompass:
-
Chemical composition: Patented formulations comprising a specific class of compounds, particularly 2-[(4-isocyanatophenyl)amino]-4-methylpentanoic acid derivatives.
-
Methods of synthesis: Processes involving the preparation of these derivatives with enhanced stability and bioavailability.
-
Therapeutic applications: Use of these formulations in treating autoimmune conditions like rheumatoid arthritis, psoriasis, and related inflammatory disorders.
B. Claims Structure and Breadth
| Claim Type |
Number of Claims |
Description |
Scope |
| Composition Claims |
8 |
Specific formulations of the compound, often involving stabilizers, excipients, and dosage forms |
Broad within the class of compounds, focusing on stability and bioavailability |
| Method Claims |
4 |
Techniques for manufacturing the formulations |
Specific, but covering multiple synthesis routes |
| Use Claims |
2 |
Use of the compounds in specific diseases |
Narrower, tied to therapeutic indications |
Examples of key claims:
-
Claim 1: Composition comprising a therapeutically effective amount of the specified compound, stabilized via a particular method involving antioxidants or specific excipients.
-
Claim 3: A process for preparing the composition involving specific steps of synthesis and stabilization.
-
Claim 9: The use of the composition in treating inflammatory or autoimmune diseases.
III. Patent Landscape Analysis: Context & Related Patents
A. Composition & Method Patent Space
| Patent Family |
Focus |
Filing Date |
Status |
Jurisdiction |
Cited Patents |
Similarity |
| US 6,465,464 |
Active Ingredient, Stabilization, Method of Manufacturing |
1998 |
Expired in 2018 |
US |
US 5,721,183; US 5,919,818 |
High – overlaps in anti-inflammatory molecule formulations, especially methotrexate analogs |
| EP 1,003,774 |
Formulation of Methotrexate Derivatives |
1999 |
Expired |
Europe |
US 6,465,464 |
Close, covers similar chemical class |
| WO 00/54012 |
Combination Therapies |
2000 |
Expired or pending |
WO Patent Office |
US 6,465,464 |
Broader therapeutic claims |
B. Patent Filing Trends and Competition
From 1998-2008, several patents were filed in the US, Europe, and Asia focusing on:
- Stabilized formulations of methotrexate derivatives.
- Novel synthetic pathways for isocyanato compounds.
- Combination therapies with biologics or corticosteroids.
Major competitors included:
- Sandoz (Hexal), Ariad Pharmaceuticals, and other generic players.
- Biogen and Novartis targeting broader autoimmune applications.
C. Patent Litigation & Challenges
- No known litigation involving US 6,465,464 directly; however, patent expirations led to increased biosimilar entry post-2018.
- Ongoing patent applications have sought to expand claims around derivatives and formulations based on the original compound class.
IV. Analysis of Claim Scope & Patent Robustness
A. Strengths
- Specific chemical formulation: The claims precisely define the compound and stabilization methods, providing clarity.
- Therapeutic claims: Narrow but enforceable, covering specific indications like rheumatoid arthritis.
- Method claims: Sufficient detail to prevent easy workaround.
B. Limitations and Potential Challenges
- Patent expiration: The core patent has expired, allowing generic competition.
- Claim overlaps: Similar compounds and formulations from other patentee portfolios could challenge enforceability.
- Design-around possibility: Alternative compounds with comparable efficacy and stability could evade infringement.
V. Implications for Industry & Innovation
- Patent expiry has opened the market to generics, notably Sandoz’s Zarxio and other biosimilars.
- Companies have since pursued diversified formulations and combination therapies to extend exclusivity.
- The landscape suggests incremental innovation rather than radical shifts, consistent with typical therapeutics patent strategies.
VI. Comparative Summary Table
| Attribute |
U.S. Patent 6,465,464 |
Similar Patents |
Broader Patent Climate |
| Focus |
Compound stability, formulation |
Formulation of methotrexate derivatives |
Composition + therapeutic use + combination therapies |
| Claims |
Composition, method, use |
Composition and process |
Use claims, device claims, method claims |
| Patent Life |
2002–2018 |
~2000s |
1990s–present |
VII. Conclusion: Patent Landscape Summary
U.S. Patent 6,465,464 was an important step in stabilizing and enabling the commercial use of a class of anti-inflammatory compounds. Its relatively narrow but critical claims provided strong protection during its enforceable period. The expiration catalyzed the entry of biosimilars, intensifying competition but also incentivizing newer patents around derivative compounds, delivery systems, and combination strategies.
Key Takeaways
- The patent’s scope centered on specific chemical formulations, methods of preparation, and therapeutic applications, providing comprehensive protection during its active years.
- The expiration of this patent has shifted the competitive landscape towards generics, with continued innovation focusing on improved formulations and combination therapies.
- Patent landscape analysis reveals a dense cluster of related patents, emphasizing incremental innovation rather than breakthrough therapies.
- Companies aiming to develop similar compounds post-expiration should prioritize patent clearance around core compounds, process patents, and formulation rights, considering potential patent thickets.
- Future pharmaceutical strategies should focus on combination therapies, personalized medicine, and delivery mechanisms to secure patent protection once foundational patents expire.
FAQs
1. What is the primary chemical class covered by U.S. Patent 6,465,464?
It covers derivatives of 2-[(4-isocyanatophenyl)amino]-4-methylpentanoic acid, with specific formulations enhancing stability and bioavailability for anti-inflammatory therapy.
2. Has U.S. Patent 6,465,464 ever been litigated or challenged?
No publicly known litigations or challenges directly involve this patent; however, its expiration in 2018 opened broader market access for generic manufacturers.
3. What are the key elements that determine the scope of claims in this patent?
Chemical composition details, synthesis processes, stabilization methods, and therapeutic indications.
4. How does the patent landscape around this IP influence current drug development?
It encourages innovation around derivative compounds, improved formulations, and combination therapies, especially following patent expiration.
5. Are there active patents that extend or improve upon this patent's claims?
Yes, subsequent patents have sought to broaden claims or develop new formulations, but the original patent’s expiration limits its enforceability.
References
[1] U.S. Patent No. 6,465,464, "Pharmaceutical Formulations," Bayer AG, granted October 15, 2002.
[2] European Patent EP 1,003,774.
[3] World Patent WO 00/54012.
[4] FDA Drug Approval Data, 2002–2018.
[5] Patent Landscape Documentation, World Intellectual Property Organization, 1998–2018.
Note: This analysis aims to support strategic decisions by pharmaceutical developers, legal professionals, and investors involved in related therapeutic classes.
More… ↓
⤷ Start Trial
|
